Longer treatment by Vascular Biogenics Ltd.'s VB-111 showed durable tumor regression and attenuation of tumor growth in patients with recurrent glioblastoma, an aggressive cancer which begins in the brain.
The second cohort of a phase 2 trial of the drug in combination with Genentech's Avastin demonstrated favorable anti-tumor activity in terms of regression rate and overall survival following treatment through progression, as compared to a brief exposure to VB-111 with subsequent Avastin monotherapy and to historical data of Avastin monotherapy. The responses were similar for VB-111 monotherapy, including a patient who remains in complete remission after more than three years.
The company is conducting a phase 3 study comparing VB-111 in combination with Avastin to Avastin alone for the said cancer type in the U.S., Canada and Israel.
Genentech is a subsidiary of Roche Holding Ltd.